X0306 4 2022-03-30 0001281895 ROCKET PHARMACEUTICALS, INC. RCKT 0001726398 Schwartz Jonathan David C/O ROCKET PHARMACEUTICALS, INC. 9 CEDARBROOK DRIVE CRANBURY NJ 08512 true See Remarks Common Stock 2022-03-30 4 S 0 10562 15.94 D 213967 D Common Stock 2022-03-30 4 S 0 34438 16.56 D 179529 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2021, as modified. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $15.87 to $15.99, inclusive. The reporting person undertakes to provide to Rocket Pharmaceuticals, Inc., any securityholder of Rocket Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $16.00 to $16.95, inclusive. Chief Medical Officer & Clinical Development, SVP. /s/ Martin Wilson, as attorney-in-fact for Jonathan David Schwartz 2022-04-01